Source:http://linkedlifedata.com/resource/pubmed/id/18285545
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2008-4-28
|
| pubmed:abstractText |
The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:BeckJörn-DirkJD,
pubmed-author:BeierRitaR,
pubmed-author:BodeUdoU,
pubmed-author:BoosJoachimJ,
pubmed-author:DördelmannMichaelM,
pubmed-author:FeldgesAndreasA,
pubmed-author:GadnerHelmutH,
pubmed-author:German-Austrian-Swiss ALL-BFM Study Group,
pubmed-author:HarbottJochenJ,
pubmed-author:HenzeGünterG,
pubmed-author:KlingebielThomasT,
pubmed-author:LöningLutzL,
pubmed-author:LudwigWolf-DieterWD,
pubmed-author:MörickeAnjaA,
pubmed-author:MannGeorgG,
pubmed-author:NiemeyerCharlotteC,
pubmed-author:NiethammerDietrichD,
pubmed-author:NiggliFelixF,
pubmed-author:RateiRichardR,
pubmed-author:ReiterAlfredA,
pubmed-author:RiehmHansjörgH,
pubmed-author:SchrappeMartinM,
pubmed-author:StanullaMartinM,
pubmed-author:UrbanChristianC,
pubmed-author:WehingerHelmutH,
pubmed-author:WelteKarlK,
pubmed-author:ZimmermannMartinM,
pubmed-author:ZintlFelixF
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
1
|
| pubmed:volume |
111
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4477-89
|
| pubmed:dateRevised |
2009-6-2
|
| pubmed:meshHeading |
pubmed-meshheading:18285545-Adolescent,
pubmed-meshheading:18285545-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18285545-Central Nervous System Neoplasms,
pubmed-meshheading:18285545-Child,
pubmed-meshheading:18285545-Child, Preschool,
pubmed-meshheading:18285545-Cranial Irradiation,
pubmed-meshheading:18285545-Cytarabine,
pubmed-meshheading:18285545-Female,
pubmed-meshheading:18285545-Humans,
pubmed-meshheading:18285545-Infant,
pubmed-meshheading:18285545-Male,
pubmed-meshheading:18285545-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:18285545-Recurrence,
pubmed-meshheading:18285545-Risk Assessment,
pubmed-meshheading:18285545-Survival Analysis
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
|
| pubmed:affiliation |
Department of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|